Inventor
Aris BARAS
Inventor
US
Overview
Patents· 37 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes22%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms22%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C12NMicroorganisms or enzymes18%
C07KPeptides7%
C12YEnzymes6%
G01NInvestigating or analysing materials by determining their chemical or physical properties6%
C08GMacromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds1%
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology1%
PatentTitleYear
12,584,174Treatment of psoriasis with interferon induced Helicase C domain 1 (IFIH1) inhibitors202612,577,562Treatment of glaucoma with Rho Guanine Nucleotide Exchange factor 12 (ARHGEF12) inhibitors202612,472,241Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors202512,378,557Treatment of sepsis with PCSK9 and LDLR modulators202512,370,257Materials and methods of treating MHC-I-opathy risk haplotypes202512,359,20117ss-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof202512,286,677Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation202512,264,366Genome-based methods for reducing cardiovascular risk202512,258,627Kelch domain containing 7B (KLHDC7B) variants and uses thereof202512,234,460Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors202512,215,322Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors202512,186,378Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists202512,163,192Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof202412,157,891Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors202412,123,001Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors202412,070,460Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors202412,018,259Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors202411,957,704Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors202411,939,635Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)202411,891,607Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors202411,865,134Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors202411,845,989Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors202311,845,963HSD17B13 variants and uses thereof202311,820,982Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitors202311,773,393Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors202311,767,526Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors202311,759,476Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors202311,753,628HSD17B13 variants and uses thereof202311,752,197Macrophage stimulating 1 receptor (MST1R) variants and uses thereof202311,708,415Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1202311,702,700Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation202311,674,177Kelch domain containing 7B (KLHDC7B) variants and uses thereof202311,584,966Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof202311,512,309Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors202211,485,958HSD17B13 variants and uses thereof202211,359,246Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors202211,180,75717b-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to REGENERON PHARMA (37)· patent assignee history
2021–2026Based in US· patent location history
2022–2023Patents assigned to REGENERAN PHARMACEUTICALS INC (2)· patent assignee history
2024–2025Patents assigned to THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (2)· patent assignee history
2024–2025Patents assigned to THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 37 | 2021–2026 |
| REGENERAN PHARMACEUTICALS INC | 2 | 2022–2023 |
| THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV | 2 | 2024–2025 |
| THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV | 2 | 2024–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 37 | 2021–2026 |